Patent: 10,632,185
Summary for Patent: 10,632,185
| Title: | Chimeric west nile/zika viruses and methods of use |
| Abstract: | Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from West Nile virus (WNV), and a portion of a prM signal sequence, a prM protein and an E protein from Zika virus (VIKV) are described. Also described are compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV. Diagnostic assays that utilize chimeric West Nile/Zika viruses are further described. |
| Inventor(s): | Claire Y. H. Kinney |
| Assignee: | US Department of Health and Human Services |
| Application Number: | US16/315,897 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,632,185
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Biologicals | SHINGRIX | zoster vaccine recombinant, adjuvanted | Injection | 125614 | October 20, 2017 | 10,632,185 | 2037-07-06 |
| Glaxosmithkline Biologicals | SHINGRIX | zoster vaccine recombinant, adjuvanted | For Injection | 125614 | July 23, 2021 | 10,632,185 | 2037-07-06 |
| Glaxosmithkline Biologicals | SHINGRIX | zoster vaccine recombinant, adjuvanted | Injection | 125614 | July 16, 2025 | 10,632,185 | 2037-07-06 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,632,185
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| United States of America | 2019298818 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2018009603 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
